Significant improvement seen in progression-free survival and in time to next intervention for vorasidenib versus placebo<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, June 6, 2023 (HealthDay News) — Vorasidenib significantly improves progression-free survival among patients with grade 2 isocitrate dehydrogenase (IDH)-mutant glioma, according to a study published online June 4 in the New England Journal of Medicine<\/em> to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.<\/p>\n Ingo K. Mellinghoff, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues randomly assigned patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery to receive either oral vorasidenib or matched placebo (168 and 163 patients, respectively). The primary end point was imaging-based progression-free survival.<\/p>\n The researchers found that 226 patients (68.3 percent) were continuing to receive vorasidenib or placebo at a median follow-up of 14.2 months. Progression-free survival was significantly improved with vorasidenib versus placebo (27.7 versus 11.1 months; hazard ratio for disease progression or death, 0.39). Compared with the placebo group, the vorasidenib group had significantly improved time to next intervention (hazard ratio, 0.26). Adverse events of grade 3 or higher occurred in 22.8 and 13.5 percent of those who received vorasidenib and placebo, respectively. <\/p>\n “Our study shows that targeting IDH mutations with vorasidenib significantly delays tumor growth and the need for more toxic therapies,” Mellinghoff said in a statement. “This is clinically meaningful because patients diagnosed with grade 2 glioma with IDH mutations are typically young, otherwise healthy individuals. The results of this trial offer a chance to change the treatment paradigm for this type of glioma and could bring the first new targeted therapy for low-grade glioma.”<\/p>\n The study was funded by Servier, the developer of vorasidenib.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n